{"id":8204,"date":"2026-03-03T16:00:20","date_gmt":"2026-03-03T15:00:20","guid":{"rendered":"https:\/\/www.rcts.fr\/?p=8204"},"modified":"2026-03-03T10:45:08","modified_gmt":"2026-03-03T09:45:08","slug":"acoziborole-success-story-rcts","status":"publish","type":"post","link":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/","title":{"rendered":"Sleeping sickness: EMA authorizes a single\u2011dose treatment"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":7,"featured_media":8206,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false},"categories":[47,45,40],"class_list":["post-8204","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-success-stories-en","category-publications-en","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Acoziborole: A Major RCTs Success Story Against HAT<\/title>\n<meta name=\"description\" content=\"Acoziborole, a success story for RCTs, achieved a 96% success rate in Phase II\/III and marks a major breakthrough in the fight against HAT.\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acoziborole: A Major RCTs Success Story Against HAT\" \/>\n<meta property=\"og:description\" content=\"Acoziborole, a success story for RCTs, achieved a 96% success rate in Phase II\/III and marks a major breakthrough in the fight against HAT.\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/\" \/>\n<meta property=\"og:site_name\" content=\"RCTs\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T15:00:20+00:00\" \/>\n<meta name=\"author\" content=\"MBY RCTs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MBY RCTs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/\"},\"author\":{\"name\":\"MBY RCTs\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/c7923553fef383c240dda86241dd6ead\"},\"headline\":\"Sleeping sickness: EMA authorizes a single\u2011dose treatment\",\"datePublished\":\"2026-03-03T15:00:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/\"},\"wordCount\":8,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/vignette-580x430-svg-1.svg\",\"articleSection\":[\"Success stories\",\"Publications\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/\",\"name\":\"Acoziborole: A Major RCTs Success Story Against HAT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/vignette-580x430-svg-1.svg\",\"datePublished\":\"2026-03-03T15:00:20+00:00\",\"description\":\"Acoziborole, a success story for RCTs, achieved a 96% success rate in Phase II\\\/III and marks a major breakthrough in the fight against HAT.\u201d\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/vignette-580x430-svg-1.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/vignette-580x430-svg-1.svg\",\"width\":434,\"height\":322,\"caption\":\"acoziborole success story\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/acoziborole-success-story-rcts\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sleeping sickness: EMA authorizes a single\u2011dose treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"name\":\"RCTs\",\"description\":\"Description\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rcts.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#organization\",\"name\":\"RCTs\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"contentUrl\":\"https:\\\/\\\/www.rcts.fr\\\/wp-content\\\/uploads\\\/logo-blue.svg\",\"width\":163,\"height\":47,\"caption\":\"RCTs\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.rcts.fr\\\/#\\\/schema\\\/person\\\/c7923553fef383c240dda86241dd6ead\",\"name\":\"MBY RCTs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f66f3995f8ff9b6bd413a27145c1528b22a15d589b9da60a1f972b951445d2fd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f66f3995f8ff9b6bd413a27145c1528b22a15d589b9da60a1f972b951445d2fd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f66f3995f8ff9b6bd413a27145c1528b22a15d589b9da60a1f972b951445d2fd?s=96&d=mm&r=g\",\"caption\":\"MBY RCTs\"},\"url\":\"https:\\\/\\\/www.rcts.fr\\\/en\\\/author\\\/mby-rcts\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acoziborole: A Major RCTs Success Story Against HAT","description":"Acoziborole, a success story for RCTs, achieved a 96% success rate in Phase II\/III and marks a major breakthrough in the fight against HAT.\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/","og_locale":"en_US","og_type":"article","og_title":"Acoziborole: A Major RCTs Success Story Against HAT","og_description":"Acoziborole, a success story for RCTs, achieved a 96% success rate in Phase II\/III and marks a major breakthrough in the fight against HAT.\u201d","og_url":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/","og_site_name":"RCTs","article_published_time":"2026-03-03T15:00:20+00:00","author":"MBY RCTs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"MBY RCTs","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#article","isPartOf":{"@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/"},"author":{"name":"MBY RCTs","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/c7923553fef383c240dda86241dd6ead"},"headline":"Sleeping sickness: EMA authorizes a single\u2011dose treatment","datePublished":"2026-03-03T15:00:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/"},"wordCount":8,"publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"image":{"@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/vignette-580x430-svg-1.svg","articleSection":["Success stories","Publications"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/","url":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/","name":"Acoziborole: A Major RCTs Success Story Against HAT","isPartOf":{"@id":"https:\/\/www.rcts.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#primaryimage"},"image":{"@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/vignette-580x430-svg-1.svg","datePublished":"2026-03-03T15:00:20+00:00","description":"Acoziborole, a success story for RCTs, achieved a 96% success rate in Phase II\/III and marks a major breakthrough in the fight against HAT.\u201d","breadcrumb":{"@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#primaryimage","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/vignette-580x430-svg-1.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/vignette-580x430-svg-1.svg","width":434,"height":322,"caption":"acoziborole success story"},{"@type":"BreadcrumbList","@id":"https:\/\/www.rcts.fr\/en\/acoziborole-success-story-rcts\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.rcts.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Sleeping sickness: EMA authorizes a single\u2011dose treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.rcts.fr\/#website","url":"https:\/\/www.rcts.fr\/","name":"RCTs","description":"Description","publisher":{"@id":"https:\/\/www.rcts.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rcts.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rcts.fr\/#organization","name":"RCTs","url":"https:\/\/www.rcts.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","contentUrl":"https:\/\/www.rcts.fr\/wp-content\/uploads\/logo-blue.svg","width":163,"height":47,"caption":"RCTs"},"image":{"@id":"https:\/\/www.rcts.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.rcts.fr\/#\/schema\/person\/c7923553fef383c240dda86241dd6ead","name":"MBY RCTs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f66f3995f8ff9b6bd413a27145c1528b22a15d589b9da60a1f972b951445d2fd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f66f3995f8ff9b6bd413a27145c1528b22a15d589b9da60a1f972b951445d2fd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f66f3995f8ff9b6bd413a27145c1528b22a15d589b9da60a1f972b951445d2fd?s=96&d=mm&r=g","caption":"MBY RCTs"},"url":"https:\/\/www.rcts.fr\/en\/author\/mby-rcts\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/8204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/comments?post=8204"}],"version-history":[{"count":1,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/8204\/revisions"}],"predecessor-version":[{"id":8215,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/posts\/8204\/revisions\/8215"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media\/8206"}],"wp:attachment":[{"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/media?parent=8204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rcts.fr\/en\/wp-json\/wp\/v2\/categories?post=8204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}